Re­gen­eron’s star bis­pe­cif­ic is linked to 2 deaths in a small study — which was no help for its Q1 call

One of Re­gen­eron’s star can­cer drugs in the pipeline has run in­to trou­ble, and that’s con­tribut­ing to some tur­bu­lence for the share price on Tues­day.

Re­gen­eron ex­ecs chose to dis­close in their Q1 call with an­a­lysts to­day that their close­ly watched bis­pe­cif­ic REGN1979 was linked with two deaths from cy­tokine re­lease syn­drome in a small PD-1 com­bo study in­volv­ing 30 pa­tients. 

This bis­pe­cif­ic hunts the B cell mark­er CD20 as well as the CD3 com­po­nent of the T cell re­cep­tor, and Re­gen­eron can­cer re­search chief Is­rael Lowy spot­light­ed a 100% over­all re­sponse rate as a monother­a­py at ASH late last year, with 8 com­plete re­spons­es and 2 par­tials among pa­tients with fol­lic­u­lar lym­phoma. That’s very ear­ly-stage da­ta from a tiny tri­al, but Phase I is the new Phase II in can­cer re­search, and those kinds of da­ta al­ways at­tract at­ten­tion in the field — par­tic­u­lar­ly when it comes from a high-pro­file out­fit like Re­gen­eron.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER